Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) EBIT Margin (2021 - 2025)

Kiniksa Pharmaceuticals International's EBIT Margin history spans 5 years, with the latest figure at 9.78% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 2553.0% year-over-year to 9.78%; the TTM value through Dec 2025 reached 11.4%, up 2217.0%, while the annual FY2025 figure was 11.4%, 2217.0% up from the prior year.
  • EBIT Margin reached 9.78% in Q4 2025 per KNSA's latest filing, down from 13.28% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 46.82% in Q3 2022 to a low of 526.41% in Q2 2021.
  • Average EBIT Margin over 5 years is 58.82%, with a median of 8.61% recorded in 2024.
  • Peak YoY movement for EBIT Margin: skyrocketed 45461bps in 2022, then crashed -6312bps in 2023.
  • A 5-year view of EBIT Margin shows it stood at 192.75% in 2021, then skyrocketed by 98bps to 4.08% in 2022, then skyrocketed by 102bps to 0.1% in 2023, then crashed by -16315bps to 15.75% in 2024, then soared by 162bps to 9.78% in 2025.
  • Per Business Quant, the three most recent readings for KNSA's EBIT Margin are 9.78% (Q4 2025), 13.28% (Q3 2025), and 12.86% (Q2 2025).